Immunotechnology

ADMA Biologics Announces Commercial Relaunch and
its First Commercial Sales of BIVIGAM®

see the press release

Innovation for the immunocompromised

Our goal is to be a leader in developing and commercializing specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised.